Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/NRG1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/NRG1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/NRG1_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/NRG1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006053717 | Skin | SCCIS | muscle tissue development | 43/919 | 403/18723 | 1.50e-06 | 8.89e-05 | 43 |
GO:005127116 | Skin | SCCIS | negative regulation of cellular component movement | 40/919 | 367/18723 | 2.04e-06 | 1.09e-04 | 40 |
GO:0048732112 | Skin | SCCIS | gland development | 45/919 | 436/18723 | 2.12e-06 | 1.09e-04 | 45 |
GO:004349115 | Skin | SCCIS | protein kinase B signaling | 27/919 | 211/18723 | 5.07e-06 | 2.09e-04 | 27 |
GO:003033615 | Skin | SCCIS | negative regulation of cell migration | 37/919 | 344/18723 | 6.66e-06 | 2.64e-04 | 37 |
GO:0038127110 | Skin | SCCIS | ERBB signaling pathway | 19/919 | 121/18723 | 6.72e-06 | 2.64e-04 | 19 |
GO:005080814 | Skin | SCCIS | synapse organization | 42/919 | 426/18723 | 1.43e-05 | 4.70e-04 | 42 |
GO:005105616 | Skin | SCCIS | regulation of small GTPase mediated signal transduction | 33/919 | 302/18723 | 1.49e-05 | 4.86e-04 | 33 |
GO:007037114 | Skin | SCCIS | ERK1 and ERK2 cascade | 35/919 | 330/18723 | 1.59e-05 | 4.98e-04 | 35 |
GO:005189715 | Skin | SCCIS | positive regulation of protein kinase B signaling | 18/919 | 120/18723 | 2.22e-05 | 6.50e-04 | 18 |
GO:000726517 | Skin | SCCIS | Ras protein signal transduction | 35/919 | 337/18723 | 2.48e-05 | 6.96e-04 | 35 |
GO:0033674110 | Skin | SCCIS | positive regulation of kinase activity | 44/919 | 467/18723 | 2.75e-05 | 7.56e-04 | 44 |
GO:001470616 | Skin | SCCIS | striated muscle tissue development | 38/919 | 384/18723 | 3.33e-05 | 8.88e-04 | 38 |
GO:005189615 | Skin | SCCIS | regulation of protein kinase B signaling | 23/919 | 185/18723 | 3.96e-05 | 1.01e-03 | 23 |
GO:004269215 | Skin | SCCIS | muscle cell differentiation | 37/919 | 384/18723 | 7.38e-05 | 1.71e-03 | 37 |
GO:0042177112 | Skin | SCCIS | negative regulation of protein catabolic process | 17/919 | 121/18723 | 8.66e-05 | 1.98e-03 | 17 |
GO:006109711 | Skin | SCCIS | regulation of protein tyrosine kinase activity | 14/919 | 90/18723 | 1.19e-04 | 2.49e-03 | 14 |
GO:00703725 | Skin | SCCIS | regulation of ERK1 and ERK2 cascade | 31/919 | 309/18723 | 1.34e-04 | 2.77e-03 | 31 |
GO:002178211 | Skin | SCCIS | glial cell development | 16/919 | 116/18723 | 1.72e-04 | 3.35e-03 | 16 |
GO:004341014 | Skin | SCCIS | positive regulation of MAPK cascade | 42/919 | 480/18723 | 2.15e-04 | 4.02e-03 | 42 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
hsa0152110 | Esophagus | ESCC | EGFR tyrosine kinase inhibitor resistance | 55/4205 | 79/8465 | 2.44e-04 | 8.78e-04 | 4.50e-04 | 55 |
hsa0401218 | Esophagus | ESCC | ErbB signaling pathway | 56/4205 | 85/8465 | 1.78e-03 | 5.24e-03 | 2.68e-03 | 56 |
hsa0501438 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
hsa0152115 | Esophagus | ESCC | EGFR tyrosine kinase inhibitor resistance | 55/4205 | 79/8465 | 2.44e-04 | 8.78e-04 | 4.50e-04 | 55 |
hsa0401219 | Esophagus | ESCC | ErbB signaling pathway | 56/4205 | 85/8465 | 1.78e-03 | 5.24e-03 | 2.68e-03 | 56 |
hsa0501428 | Oral cavity | OSCC | Amyotrophic lateral sclerosis | 246/3704 | 364/8465 | 6.65e-21 | 1.11e-18 | 5.67e-19 | 246 |
hsa015219 | Oral cavity | OSCC | EGFR tyrosine kinase inhibitor resistance | 54/3704 | 79/8465 | 8.11e-06 | 3.72e-05 | 1.89e-05 | 54 |
hsa0401216 | Oral cavity | OSCC | ErbB signaling pathway | 55/3704 | 85/8465 | 7.46e-05 | 2.81e-04 | 1.43e-04 | 55 |
hsa05014112 | Oral cavity | OSCC | Amyotrophic lateral sclerosis | 246/3704 | 364/8465 | 6.65e-21 | 1.11e-18 | 5.67e-19 | 246 |
hsa0152114 | Oral cavity | OSCC | EGFR tyrosine kinase inhibitor resistance | 54/3704 | 79/8465 | 8.11e-06 | 3.72e-05 | 1.89e-05 | 54 |
hsa0401217 | Oral cavity | OSCC | ErbB signaling pathway | 55/3704 | 85/8465 | 7.46e-05 | 2.81e-04 | 1.43e-04 | 55 |
hsa0501426 | Prostate | BPH | Amyotrophic lateral sclerosis | 151/1718 | 364/8465 | 3.37e-21 | 1.01e-19 | 6.25e-20 | 151 |
hsa015218 | Prostate | BPH | EGFR tyrosine kinase inhibitor resistance | 30/1718 | 79/8465 | 2.10e-04 | 1.13e-03 | 6.98e-04 | 30 |
hsa0401214 | Prostate | BPH | ErbB signaling pathway | 28/1718 | 85/8465 | 4.12e-03 | 1.45e-02 | 8.95e-03 | 28 |
hsa05014111 | Prostate | BPH | Amyotrophic lateral sclerosis | 151/1718 | 364/8465 | 3.37e-21 | 1.01e-19 | 6.25e-20 | 151 |
hsa0152113 | Prostate | BPH | EGFR tyrosine kinase inhibitor resistance | 30/1718 | 79/8465 | 2.10e-04 | 1.13e-03 | 6.98e-04 | 30 |
hsa0401215 | Prostate | BPH | ErbB signaling pathway | 28/1718 | 85/8465 | 4.12e-03 | 1.45e-02 | 8.95e-03 | 28 |
hsa0501427 | Prostate | Tumor | Amyotrophic lateral sclerosis | 155/1791 | 364/8465 | 3.41e-21 | 1.13e-19 | 6.99e-20 | 155 |
hsa0152123 | Prostate | Tumor | EGFR tyrosine kinase inhibitor resistance | 31/1791 | 79/8465 | 1.82e-04 | 1.08e-03 | 6.68e-04 | 31 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NRG1 | SNV | Missense_Mutation | novel | c.514N>T | p.Ala172Ser | p.A172S | Q02297 | protein_coding | tolerated(0.7) | benign(0.031) | TCGA-AC-A8OR-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NRG1 | SNV | Missense_Mutation | novel | c.464N>T | p.Arg155Ile | p.R155I | Q02297 | protein_coding | tolerated(0.16) | possibly_damaging(0.642) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
NRG1 | SNV | Missense_Mutation | | c.1639N>A | p.Ala547Thr | p.A547T | Q02297 | protein_coding | tolerated(0.29) | benign(0.001) | TCGA-LL-A73Z-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
NRG1 | SNV | Missense_Mutation | novel | c.53N>A | p.Arg18Gln | p.R18Q | Q02297 | protein_coding | tolerated(0.45) | benign(0.091) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
NRG1 | insertion | Nonsense_Mutation | novel | c.1795_1796insTCTACTTCTCGTGACACCACCAAGGCTGCGGGAGAAGAAGTTTGA | p.Pro599delinsLeuTyrPheSerTerHisHisGlnGlyCysGlyArgArgSerLeuThr | p.P599delinsLYFS*HHQGCGRRSLT | Q02297 | protein_coding | | | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
NRG1 | insertion | Frame_Shift_Ins | novel | c.1743_1744insCCATCACCCTCAGCAGTTCAGCTCCTTCCACC | p.Thr582ProfsTer17 | p.T582Pfs*17 | Q02297 | protein_coding | | | TCGA-A8-A07Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Exemestane | SD |
NRG1 | SNV | Missense_Mutation | novel | c.1813N>C | p.Glu605Gln | p.E605Q | Q02297 | protein_coding | deleterious(0.04) | probably_damaging(0.966) | TCGA-C5-A2LZ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Unknown | Unknown | PD |
NRG1 | SNV | Missense_Mutation | rs146885321 | c.292C>T | p.Arg98Cys | p.R98C | Q02297 | protein_coding | deleterious(0) | possibly_damaging(0.899) | TCGA-VS-A8EK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
NRG1 | SNV | Missense_Mutation | | c.289C>A | p.Leu97Ile | p.L97I | Q02297 | protein_coding | tolerated(0.09) | probably_damaging(0.998) | TCGA-A6-5657-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Ancillary | leucovorin | SD |
NRG1 | SNV | Missense_Mutation | | c.5G>T | p.Arg2Ile | p.R2I | Q02297 | protein_coding | deleterious_low_confidence(0) | benign(0.053) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
3084 | NRG1 | GROWTH FACTOR, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE, KINASE | | NERVE GROWTH FACTOR | | 11069896 |
3084 | NRG1 | GROWTH FACTOR, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE, KINASE | | PERTUZUMAB | PERTUZUMAB | 29802158 |
3084 | NRG1 | GROWTH FACTOR, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE, KINASE | | ANTI-HER3 MONOCLONAL ANTIBODY GSK2849330 | | 29610121 |
3084 | NRG1 | GROWTH FACTOR, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE, KINASE | | PROGESTERONE | PROGESTERONE | 12529413 |
3084 | NRG1 | GROWTH FACTOR, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE, KINASE | | ISOPROTERENOL | ISOPROTERENOL | 14732742 |
3084 | NRG1 | GROWTH FACTOR, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE, KINASE | | ASPIRIN | ASPIRIN | 10921413 |
3084 | NRG1 | GROWTH FACTOR, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE, KINASE | | DEXAMETHASONE | DEXAMETHASONE | 7599067 |
3084 | NRG1 | GROWTH FACTOR, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE, KINASE | | CISPLATIN | CISPLATIN | 23390248 |
3084 | NRG1 | GROWTH FACTOR, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE, KINASE | | WORTMANNIN | WORTMANNIN | 10559227 |
3084 | NRG1 | GROWTH FACTOR, CLINICALLY ACTIONABLE, DRUGGABLE GENOME, DRUG RESISTANCE, KINASE | | GENISTEIN | GENISTEIN | 17539658 |